Matthew W. Foehr Sells 13,964 Shares of OmniAb, Inc. (NASDAQ:OABI) Stock

OmniAb, Inc. (NASDAQ:OABI) CEO Matthew W. Foehr sold 13,964 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.68, for a total transaction of $51,387.52. Following the completion of the transaction, the chief executive officer now directly owns 3,798,682 shares of the company’s stock, valued at approximately $13,979,149.76. The trade was a 0.37 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

OmniAb Stock Performance

Shares of NASDAQ OABI opened at $3.88 on Friday. OmniAb, Inc. has a fifty-two week low of $3.10 and a fifty-two week high of $6.55. The company has a 50 day simple moving average of $3.49 and a two-hundred day simple moving average of $3.91. The company has a market capitalization of $547.93 million, a price-to-earnings ratio of -6.26 and a beta of -0.12.

Analysts Set New Price Targets

A number of research firms recently issued reports on OABI. Benchmark reissued a “buy” rating and issued a $8.00 price target on shares of OmniAb in a research note on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of OmniAb in a research note on Thursday, November 14th.

Hedge Funds Weigh In On OmniAb

A number of institutional investors and hedge funds have recently made changes to their positions in OABI. SG Americas Securities LLC increased its stake in shares of OmniAb by 105.6% during the third quarter. SG Americas Securities LLC now owns 34,858 shares of the company’s stock valued at $147,000 after purchasing an additional 17,901 shares in the last quarter. CWC Advisors LLC. bought a new position in shares of OmniAb during the third quarter valued at approximately $54,000. China Universal Asset Management Co. Ltd. increased its stake in shares of OmniAb by 64.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company’s stock valued at $96,000 after purchasing an additional 8,909 shares in the last quarter. Palumbo Wealth Management LLC increased its stake in shares of OmniAb by 12.5% during the third quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock valued at $104,000 after purchasing an additional 2,744 shares in the last quarter. Finally, Rice Hall James & Associates LLC increased its stake in shares of OmniAb by 6.4% during the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock valued at $11,515,000 after purchasing an additional 163,038 shares in the last quarter. Institutional investors own 72.08% of the company’s stock.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.